chr2-47414420-T-C
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1_ModeratePP5_Very_Strong
The NM_000251.3(MSH2):c.942+2T>C variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000251.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 11
GnomAD4 exome Cov.: 18
GnomAD4 genome Cov.: 11
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. Functional studies indicate this variant impacts protein function [PMID: 8062247]. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change affects a donor splice site in intron 5 of the MSH2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 20591884, 21239990, 24278394). ClinVar contains an entry for this variant (Variation ID: 142750). Studies have shown disruption of this splice site is associated with skipping of exon 5, but one or more of the resulting mRNA isoform(s) may be naturally occurring (Invitae). This variant disrupts a region of the MSH2 protein in which other variant(s) (p.Leu310Pro) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.942+2T>C intronic pathogenic mutation results from a T to C substitution two nucleotides after coding exon 5 in the MSH2 gene. While this pathogenic mutation has not been reported in the literature to date, two different pathogenic mutations at the same nucleotide position, c.942+2T>G and c.942+2T>A, have previously been reported in individuals with HNPCC (van der Post RS et al. J. Med. Genet. 2010 Jul;47(7):464-70; Parc Y et al. J. Med. Genet. 2003 Mar;40(3):208-13;De Lellis L et al. PLoS ONE 2013 ;8(11):e81194; Pastrello C et al. Genet. Med. 2011 Feb;13(2):115-24). The c.942+2T>C intronic pathogenic mutation has been detected in a family meeting Amsterdam criteria with correlating absent MSH2 staining on IHC (internal Ambry data). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at